Asset Details
Do you wish to reserve the book?
Circulating immune biomarkers correlating with response in patients with metastatic renal cell carcinoma on immunotherapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Circulating immune biomarkers correlating with response in patients with metastatic renal cell carcinoma on immunotherapy
Do you wish to request the book?
Circulating immune biomarkers correlating with response in patients with metastatic renal cell carcinoma on immunotherapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Circulating immune biomarkers correlating with response in patients with metastatic renal cell carcinoma on immunotherapy
2025
Overview
Since multiple front-line immune checkpoint inhibitor-based (ICI-based) combinations are approved for metastatic renal cell carcinoma, biomarkers predicting for ICI responses are needed past clinical prognostication scores and transcriptome gene expression profiling. Circulating markers represent opportunities to assess baseline and dynamic changes in immune cell frequency and cytokine levels while on treatment. We conducted an exploratory prospective correlative study of 33 patients with metastatic clear cell renal cell carcinoma undergoing treatment with ICIs and correlated changes in circulating immune cell subsets and cytokines with clinical responses to treatment. Cell frequencies and cytokine levels were compared between responders and nonresponders using unpaired parametric t tests, using prespecified alpha level of significance of 0.05. Classical monocyte subsets (CD14+CD16-), as well as 7 cytokines (IL-12/23 p40, macrophage inflammatory protein-1a, macrophage inflammatory protein-1b, vascular cell adhesion molecule-1, intercellular adhesion molecule-1, IL-8, and TNF-α) were higher at baseline for responding versus nonresponding patients. Dynamic changes in thymus- and activation-regulated chemokine (TARC), placental growth factor (PlGF), and vascular endothelial growth factor (VEGF) also correlated with patients with ICI response. In summary, macrophage-activating agents were observed to be important in ICI response and may highlight the importance of the innate immune response in ICI responses.
Publisher
American Society for Clinical Investigation,American Society for Clinical investigation
Subject
/ Aged
/ Biomarkers, Tumor - immunology
/ Carcinoma, Renal Cell - blood
/ Carcinoma, Renal Cell - drug therapy
/ Carcinoma, Renal Cell - immunology
/ Carcinoma, Renal Cell - therapy
/ Clear cell-type renal cell carcinoma
/ Female
/ Humans
/ Immune checkpoint inhibitors
/ Immune Checkpoint Inhibitors - therapeutic use
/ Intercellular adhesion molecule 1
/ Kidney Neoplasms - drug therapy
/ Kidney Neoplasms - immunology
/ Kidney Neoplasms - pathology
/ Kinases
/ Macrophage inflammatory protein
/ Male
/ Oncology
/ Patients
/ Tumors
Seems like something went wrong :( Kindly try again later!